Andrea Reis, Medical Manager at Further Group, Integrative Medicine Specialist, shared a post on LinkedIn:
“One of the highlights of my time at ASCO 2026 was attending the OncoDaily Grand Rounds: Sarcoma Edition.”
Sarcoma remains a challenging and rapidly evolving field, and it was a privilege to hear leading experts discuss some of the most exciting developments shaping patient care today – from biomarker testing and targeted therapies to immuno-oncology combinations, T-cell receptor therapies, and emerging antibody-drug conjugates.
A special congratulations to Robin Jones, one of the experts from Further’s international network, for his excellent presentation on targeted therapies and biomarker testing. As precision oncology continues to advance, understanding how to identify the right patients for the right treatments is becoming increasingly important, and Prof. Jones shared valuable insights from both clinical practice and research.
My congratulations also to Sandra D’Angelo, Herbert Loong, and Javier Martín-Broto for an outstanding scientific program and engaging discussions.
I would also like to recognize Amalya Sargsyan and the entire OncoDaily team for the excellent organization of this event. Bringing together world-class experts, meaningful discussions, and opportunities for networking is no small task, and the session was a great success.
As Medical Manager at Further, events like this reinforce the importance of global collaboration and access to expert knowledge. Behind every innovation presented at meetings such as ASCO are patients looking for answers, and connecting them with leading specialists remains one of the most meaningful ways to help improve outcomes.
Thank you to everyone involved for a fantastic session and for continuing to advance the conversation around sarcoma care.”
You can also read:
OncoDaily Sarcoma Grand Rounds Highlights
Other articles about ASCO26 on OncoDaily.
